PHREESIA INC (PHR) Stock Fundamental Analysis
NYSE:PHR - New York Stock Exchange, Inc. - US71944F1066 - Common Stock - Currency: USD
Taking everything into account, PHR scores 4 out of 10 in our fundamental rating. PHR was compared to 36 industry peers in the Health Care Technology industry. PHR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, PHR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PHR has reported negative net income.
In the past year PHR had a positive cash flow from operations.
PHR had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: PHR reported negative operating cash flow in multiple years.
1.2 Ratios
PHR has a Return On Assets of -10.67%. This is comparable to the rest of the industry: PHR outperforms 58.33% of its industry peers.
Looking at the Return On Equity, with a value of -15.14%, PHR is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -15.14% | ||
| ROIC | N/A |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHR has a Gross Margin of 68.02%. This is in the better half of the industry: PHR outperforms 69.44% of its industry peers.
PHR's Gross Margin has been stable in the last couple of years.
PHR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
PHR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHR has more shares outstanding than it did 1 year ago.
PHR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHR is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.07 indicates that PHR is not in any danger for bankruptcy at the moment.
PHR's Altman-Z score of 6.07 is amongst the best of the industry. PHR outperforms 83.33% of its industry peers.
The Debt to FCF ratio of PHR is 0.66, which is an excellent value as it means it would take PHR, only 0.66 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.66, PHR belongs to the top of the industry, outperforming 80.56% of the companies in the same industry.
PHR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, PHR is in line with its industry, outperforming 58.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.66 | ||
| Altman-Z | 6.07 |
ROIC/WACCN/A
WACC10.73%
2.3 Liquidity
A Current Ratio of 1.95 indicates that PHR should not have too much problems paying its short term obligations.
The Current ratio of PHR (1.95) is comparable to the rest of the industry.
A Quick Ratio of 1.95 indicates that PHR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.95, PHR is in line with its industry, outperforming 58.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.65% over the past year.
Looking at the last year, PHR shows a quite strong growth in Revenue. The Revenue has grown by 16.29% in the last year.
Measured over the past years, PHR shows a very strong growth in Revenue. The Revenue has been growing by 27.46% on average per year.
EPS 1Y (TTM)35.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)16.29%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.54%
3.2 Future
The Earnings Per Share is expected to grow by 38.94% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.19% on average over the next years. This is quite good.
EPS Next Y85.52%
EPS Next 2Y49.7%
EPS Next 3Y38.94%
EPS Next 5YN/A
Revenue Next Year13.81%
Revenue Next 2Y12.69%
Revenue Next 3Y12.38%
Revenue Next 5Y12.19%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHR. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 101.41 indicates a quite expensive valuation of PHR.
PHR's Price/Forward Earnings ratio is in line with the industry average.
PHR is valuated expensively when we compare the Price/Forward Earnings ratio to 36.52, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 101.41 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, PHR is valued a bit cheaper than the industry average as 61.11% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 67.71 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PHR's earnings are expected to grow with 38.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y38.94%
5. Dividend
5.1 Amount
PHR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:PHR (7/18/2025, 11:00:22 AM)
24.94
-0.99 (-3.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners97.92%
Inst Owner Change0%
Ins Owners4.72%
Ins Owner Change-1.25%
Market Cap1.48B
Analysts85.26
Price Target32.25 (29.31%)
Short Float %6.3%
Short Ratio6.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.24%
Min EPS beat(2)38.81%
Max EPS beat(2)41.66%
EPS beat(4)4
Avg EPS beat(4)25.79%
Min EPS beat(4)8.94%
Max EPS beat(4)41.66%
EPS beat(8)8
Avg EPS beat(8)25.32%
EPS beat(12)12
Avg EPS beat(12)23.1%
EPS beat(16)14
Avg EPS beat(16)4.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.24%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)-0.18%
Revenue beat(4)0
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-0.59%
Max Revenue beat(4)-0.18%
Revenue beat(8)2
Avg Revenue beat(8)-0.12%
Revenue beat(12)6
Avg Revenue beat(12)0.6%
Revenue beat(16)10
Avg Revenue beat(16)1.9%
PT rev (1m)0.59%
PT rev (3m)-3.22%
EPS NQ rev (1m)-2.74%
EPS NQ rev (3m)26.29%
EPS NY rev (1m)34.76%
EPS NY rev (3m)28.14%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 101.41 | ||
| P/S | 3.42 | ||
| P/FCF | 67.71 | ||
| P/OCF | 30.95 | ||
| P/B | 5.26 | ||
| P/tB | 11.82 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.74
EYN/A
EPS(NY)0.25
Fwd EY0.99%
FCF(TTM)0.37
FCFY1.48%
OCF(TTM)0.81
OCFY3.23%
SpS7.3
BVpS4.74
TBVpS2.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.67% | ||
| ROE | -15.14% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.02% | ||
| FCFM | 5.04% |
ROA(3y)-33.2%
ROA(5y)-26.37%
ROE(3y)-45.91%
ROE(5y)-35.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.16%
GM growth 5Y1.12%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.66 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.68% | ||
| Cap/Sales | 5.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.95 | ||
| Quick Ratio | 1.95 | ||
| Altman-Z | 6.07 |
F-Score7
WACC10.73%
ROIC/WACCN/A
Cap/Depr(3y)91.68%
Cap/Depr(5y)107.3%
Cap/Sales(3y)7.37%
Cap/Sales(5y)9.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y85.52%
EPS Next 2Y49.7%
EPS Next 3Y38.94%
EPS Next 5YN/A
Revenue 1Y (TTM)16.29%
Revenue growth 3Y25.34%
Revenue growth 5Y27.46%
Sales Q2Q%14.54%
Revenue Next Year13.81%
Revenue Next 2Y12.69%
Revenue Next 3Y12.38%
Revenue Next 5Y12.19%
EBIT growth 1Y64.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year236.17%
EBIT Next 3Y64.12%
EBIT Next 5Y36.17%
FCF growth 1Y122.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y168.36%
OCF growth 3YN/A
OCF growth 5Y108.09%